Show simple item record

Discovery of the natural anti-Gal antibody and its past and future relevance to medicine

dc.contributor.authorGalili, Uri
dc.date2022-08-11T08:08:34.000
dc.date.accessioned2022-08-23T15:59:35Z
dc.date.available2022-08-23T15:59:35Z
dc.date.issued2013-05-01
dc.date.submitted2013-07-02
dc.identifier.citationXenotransplantation. 2013 May/June;20(3): 138–147. doi: 10.1111/xen.12034. <a href="http://dx.doi.org/10.1111/xen.12034">Link to article on publisher's site</a>
dc.identifier.issn0908-665X (Linking)
dc.identifier.doi10.1111/xen.12034
dc.identifier.pmid23577774
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30701
dc.description.abstractThis is a personal account of the discovery of the natural anti-Gal antibody, the most abundant natural antibody in humans, the reciprocal distribution of this antibody and its ligand the alpha-gal epitope in mammals and the immunological barrier this antibody has formed in porcine to human xenotransplantation. This barrier has been overcome in the recent decade with the generation of alpha1,3-galactosyltransferase gene-knockout pigs. However, anti-Gal continues to be relevant in medicine as it can be harnessed for various therapeutic effects. Anti-Gal converts tumor lesions injected with alpha-gal glycolipids into vaccines that elicit a protective anti-tumor immune response by in situ targeting of tumor cells for uptake by antigen-presenting cells. This antibody further accelerates wound and burn healing by interaction with alpha-gal nanoparticles applied to injured areas and induction of rapid recruitment and activation of macrophages. Anti-Gal/alpha-gal nanoparticle immune complexes may further induce rapid recruitment and activation of macrophages in ischemic myocardium and injured nerves, thereby inducing tissue regeneration and prevention of fibrosis.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23577774&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1111/xen.12034
dc.subjectTransplantation, Heterologous
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectBiochemistry
dc.subjectImmunopathology
dc.subjectSurgery
dc.titleDiscovery of the natural anti-Gal antibody and its past and future relevance to medicine
dc.typeJournal Article
dc.source.journaltitleXenotransplantation
dc.source.volume20
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/98
dc.identifier.contextkey4276313
html.description.abstract<p>This is a personal account of the discovery of the natural anti-Gal antibody, the most abundant natural antibody in humans, the reciprocal distribution of this antibody and its ligand the alpha-gal epitope in mammals and the immunological barrier this antibody has formed in porcine to human xenotransplantation. This barrier has been overcome in the recent decade with the generation of alpha1,3-galactosyltransferase gene-knockout pigs. However, anti-Gal continues to be relevant in medicine as it can be harnessed for various therapeutic effects. Anti-Gal converts tumor lesions injected with alpha-gal glycolipids into vaccines that elicit a protective anti-tumor immune response by in situ targeting of tumor cells for uptake by antigen-presenting cells. This antibody further accelerates wound and burn healing by interaction with alpha-gal nanoparticles applied to injured areas and induction of rapid recruitment and activation of macrophages. Anti-Gal/alpha-gal nanoparticle immune complexes may further induce rapid recruitment and activation of macrophages in ischemic myocardium and injured nerves, thereby inducing tissue regeneration and prevention of fibrosis.</p>
dc.identifier.submissionpathfaculty_pubs/98
dc.contributor.departmentDepartment of Surgery
dc.source.pages138–147


This item appears in the following Collection(s)

Show simple item record